A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
Abstract Precision oncology is currently based on pairing molecularly targeted agents (MTA) to predefined single driver genes or biomarkers. Each tumor harbors a combination of a large number of potential genetic alterations of multiple driver genes in a complex system that limits the potential of t...
Main Authors: | Istvan Petak, Maud Kamal, Anna Dirner, Ivan Bieche, Robert Doczi, Odette Mariani, Peter Filotas, Anne Salomon, Barbara Vodicska, Vincent Servois, Edit Varkondi, David Gentien, Dora Tihanyi, Patricia Tresca, Dora Lakatos, Nicolas Servant, Julia Deri, Pauline du Rusquec, Csilla Hegedus, Diana Bello Roufai, Richard Schwab, Celia Dupain, Istvan T. Valyi-Nagy, Christophe Le Tourneau |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-021-00191-2 |
Similar Items
-
Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, <i>ALK</i>-Positive, <i>TP53</i>-Mutant NSCLC
by: László Urbán, et al.
Published: (2020-08-01) -
Fine‐needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next‐generation sequencing in cancer patients included in the SHIVA02 trial
by: Célia Dupain, et al.
Published: (2021-01-01) -
Shiva's Dance
by: Phoboo, Abha E
Published: (2012) -
Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome
by: Maud Kamal, et al.
Published: (2018-05-01) -
A Report on “The Dance of Shiva”
by: CHEN, YEN-TING, et al.
Published: (2017)